KAT7 and colorectal carcinoma: Since our results indicate that the HAT activity of KAT7 is critical for the survival of CRC cells and the activation of the MAPK/ERK signaling pathway, we next utilized a small molecule inhibitor, WM-3835, which significantly suppresses the HAT activity of KAT7 21, to investigate its potential anti-CRC effects.